Entrada Therapeutics, Inc. TRDA
As ofNov 18, 2026, 1:33 PM EST
- YTD
- -48.91%
- 1 year
- -40.45%
TRDA free cash flow history
Free cash flow is operating cash flow minus capital expenditure outflow. It can be negative; it is not the same as earnings.
-129,553,000 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Capital expenditure here is net of asset disposals, so free cash flow can be higher than a figure that subtracts gross purchases.
Scroll the table to see all values →
| Fiscal period | Period end | Free cash flow | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | -129,553,000 | -84,838,000 | Not meaningful |
| FY 2024 | 2024-12-31 | -44,715,000 | -178,904,000 | -133.32% |
| FY 2023 | 2023-12-31 | 134,189,000 | 230,862,000 | Not meaningful |
| FY 2022 | 2022-12-31 | -96,673,000 | -41,231,000 | Not meaningful |
| FY 2021 | 2021-12-31 | -55,442,000 | -27,554,000 | Not meaningful |
| FY 2020 | 2020-12-31 | -27,888,000 | -16,457,000 | Not meaningful |
| FY 2019 | 2019-12-31 | -11,431,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-11-09T07:00:38.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.
